The reduction in price target by Wells Fargo, a major financial institution, could lead to a negative short-term impact on Conmed's stock price as investors adjust their expectations based on the new target. The maintenance of an Equal-Weight rating suggests a neutral outlook on the stock's performance, but the significant decrease in price target is likely to be the dominant factor influencing investor sentiment.